abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

18 Nov 2014

Author:
Access to Medicines Index

Media Kit 2014 Index

Includes:

Press release in English, German, French, Spanish, Dutch, Japanese

2014 Access to Medicine Index Key Findings    

Overall ranking analysis 2014 Access to Medicine Index    

2014 Access to Medicine Index - Executive Summary
    
Executive Summary 2014 Access to Medicine Index - PDF

Full Report 2014 Access to Medicine Index

Companies in the index (in order from highest to lowest ranked): GlaxoSmithKline; Novo Nordisk; Johnson & Johnson; Novartis AG; Gilead Sciences Inc; Merck KGaA;
Merck & Co; Sanofi; AbbVie; Bayer AG; Eisai Co. Ltd; Roche Holding AG; Bristol-Myers Squibb Co; Boehringer Ingelheim GmbH; AstraZeneca plc; Pfizer Inc.; Eli Lilly & Co; Astellas Pharma Inc.; Daiichi Sankyo Co. Ltd.; Takeda Pharmaceutical Co.

Timeline